Facebook Linkedin Twitter
Inside Precision Medicine Lilly Pays up to $2.5B for Selective PI3Kα Inhibitor  

Clinical drug development

woman lymph armpit examination. Node-Positive Breast Cancer
News & Features

Lilly Pays up to $2.5B for Selective PI3Kα Inhibitor  

0
Chronic myeloid leukemia cells or CML
News & Features

Terns Pharmaceuticals’ Allosteric Inhibitor Shows “Best-in-Class” Potential in Phase I CML Study

Chris Anderson
0
Illustration of red blood cells moving through clogged artery to indicate cholesterol build up as a result of familial hypercholesterolemia and atherosclerosis, which can be caused by high levels of lipoprotein(a) or Lp(a).
News & Features

Lipoprotein(a) Lowering Draw Between Lilly and Silence

0
Malignant peripheral nerve sheath tumors (MPNST)
News & Features

In “Quantum Leap,” Almost Half of Adults and Children with NF1 Respond to MEK Inhibitor

0
Melanoma cancer cells of human under microscope
News & Features

New Drug Combo Shows Significant Promise in Advanced Melanoma Trial 

0
Illustration of a man's torso and arms with his liver highlighted in red to indicate acute liver failure
News & Features

Novo’s Semaglutide Scores in Liver Fibrosis and MASH Trial

0
T-Cell Attacks Cancer Cell
News & Features

New Immune Cell Has Key Role in Anti-Tumor Immunity

0
Antibody drug conjugated with cytotoxic payload. Synthetic Biology
News & Features

Radiopharma Startup Alpha-9 Nets $175M Series C

0
Passkey Therapeutics
Informatics

Passkey Therapeutics Launches with Platform to Design Multifunctional Drugs

Jonathan D. Grinstein, PhD
0
Lymphoma cancer cell that can be targeted by CAR T-cell therapy
News & Features

Immunotherapy Plus Chemotherapy: A New Standard of Care for First-Line, Advanced Hodgkin Lymphoma

Alice McCarthy
0
123...19Page 1 of 19

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine